Cytokines in sjögren's syndrome

Oral Diseases

Volumn 15, Issue 8, 2009, Pages 519-526

  Roescher, N ^a,b   Tak, P P ^b   Illei, G G ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Autoimmune diseases; Cytokines; Immunology; Pathogenesis; Salivary glands

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SALIVARY GLAND DISEASE; SEX DIFFERENCE; SJOEGREN SYNDROME; UPREGULATION;

CYTOKINES; HUMANS; SALIVA; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 70349975887     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2009.01582.x     Document Type: Review

References (87)

1. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007). Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8 : 942 949.
2. Anaya JM, Mantilla RD, Correa PA (2005). Immunogenetics of primary Sjogren's syndrome in Colombians. Semin Arthritis Rheum 34 : 735 743.
3. Annunziato F, Cosmi L, Santarlasci V et al (2007). Phenotypic and functional features of human Th17 cells. J Exp Med 204 : 1849 1861.
4. Baccala R, Kono DH, Theofilopoulos AN (2005). Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204 : 9 26.
5. Bave U, Nordmark G, Lovgren T et al (2005). Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52 : 1185 1195.
6. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW et al (2007). Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27 : 660 669.
7. Bertorello R, Cordone MP, Contini P et al (2004). Increased levels of interleukin-10 in saliva of Sjogren's syndrome patients. Correlation with disease activity. Clin Exp Med 4 : 148 151.
8. Bombardieri M, Barone F, Pittoni V et al (2004). Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther 6 : R447 R456.
9. Boras VV, Cikes N, Lukac J, Cekic-Arambasin A, Virag M, Bosnjak A (2004). The significance of salivary and serum interleukin 6 and basic fibroblast growth factor levels in patients with Sjogren's syndrome. Coll Antropol 28 (Suppl. 2 305 309.
10. Brookes SM, Cohen SB, Price EJ et al (1996). T cell clones from a Sjogren's syndrome salivary gland biopsy produce high levels of IL-10. Clin Exp Immunol 103 : 268 272.
11. Chen Q, Fisher DT, Clancy KA et al (2006). Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 7 : 1299 1308.
12. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ (2007). Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 56 : 2936 2946.
13. Crane IJ, Forrester JV (2005). Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 25 : 75 102.
14. Cua DJ, Sherlock J, Chen Y et al (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 : 744 748.
15. Daniels TE, Fox PC (1992). Salivary and oral components of Sjogren's syndrome. Rheum Dis Clin North Am 18 : 571 589.
16. Daniels PJ, Gustafson SA, French D, Wang Y, DePond W, McArthur CP (2000). Interferon-mediated block in cell cycle and altered integrin expression in a differentiated salivary gland cell line (HSG) cultured on Matrigel. J Interferon Cytokine Res 20 : 1101 1109.
17. Daridon C, Devauchelle V, Hutin P et al (2007). Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 56 : 1134 1144. (Pubitemid 46608638)
18. Dinarello CA (2007). Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27 : 98 114.
19. Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M (2006). Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 54 : 2289 2294.
20. Eriksson P, Andersson C, Ekerfelt C, Ernerudh J, Skogh T (2004). Sjogren's syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells. J Rheumatol 31 : 729 735.
21. Fox RI (2005). Sjogren's syndrome. Lancet 366 : 321 331.
22. Fox PC, Speight PM (1996). Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Crit Rev Oral Biol Med 7 : 144 158.
23. Fox RI, Kang HI, Ando D, Abrams J, Pisa E (1994). Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 152 : 5532 5539.
24. Garcic-Carrasco M, Font J, Filella X et al (2001). Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 19 : 411 415.
25. Gota C, Calabrese L (2003). Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 36 : 511 518.
26. Gottenberg JE, Busson M, Cohen-Solal J et al (2005). Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis 64 : 1050 1055.
27. Gottenberg JE, Cagnard N, Lucchesi C et al (2006). Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 103 : 2770 2775.
28. Grisius MM, Bermudez DK, Fox PC (1997). Salivary and serum interleukin 6 in primary Sjogren's syndrome. J Rheumatol 24 : 1089 1091.
29. Gross JA, Johnston J, Mudri S et al (2000). TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 : 995 999.
30. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP (2006). Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2 : 201 211.
31. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI (2005). Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 52 : 1534 1544.
32. Hu S, Wang J, Meijer J et al (2007). Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum 56 : 3588 3600. (Pubitemid 350100692)
33. Hulkkonen J, Pertovaara M, Antonen J, Lahdenpohja N, Pasternack A, Hurme M (2001a). Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren's syndrome. Arthritis Rheum 44 : 176 179.
34. Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M (2001b). Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 40 : 656 661.
35. Humphreys-Beher MG, Brayer J, Yamachika S, Peck AB, Jonsson R (1999). An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Scand J Immunol 49 : 7 10.
36. Isaacs A, Lindenmann J (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147 : 258 267.
37. Ishihara K, Hirano T (2002). IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13 : 357 368.
38. Ittah M, Miceli-Richard C, Eric Gottenberg J et al (2006). B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 8 : R51.
39. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K (2005). Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 25 : 189 201.
40. Kamachi M, Kawakami A, Yamasaki S et al (2002). Regulation of apoptotic cell death by cytokines in a human salivary gland cell line: distinct and synergistic mechanisms in apoptosis induced by tumor necrosis factor alpha and interferon gamma. J Lab Clin Med 139 : 13 19.
41. Kizu Y, Sakurai H, Katagiri S et al (1996). Immunohistological analysis of tumour growth factor beta 1 expression in normal and inflamed salivary glands. J Clin Pathol 49 : 728 732.
42. Kolkowski EC, Reth P, Pelusa F et al (1999). Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjogren's syndrome. J Autoimmun 13 : 155 162.
43. Konttinen YT, Kemppinen P, Koski H et al (1999). T(H)1 cytokines are produced in labial salivary glands in Sjogren's syndrome, but also in healthy individuals. Scand J Rheumatol 28 : 106 112.
44. Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmstrom M, Konttinen YT (2001). Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome. Clin Exp Rheumatol 19 : 131 137.
45. Kulkarni K, Selesniemi K, Brown TL (2006). Interferon-gamma sensitizes the human salivary gland cell line, HSG, to tumor necrosis factor-alpha induced activation of dual apoptotic pathways. Apoptosis 11 : 2205 2215.
46. Le Page C, Genin P, Baines MG, Hiscott J (2000). Interferon activation and innate immunity. Rev Immunogenet 2 : 374 386.
47. Mackay F, Browning JL (2002). BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2 : 465 475.
48. Mackay F, Woodcock SA, Lawton P et al (1999). Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 : 1697 1710.
49. Manoussakis MN, Boiu S, Korkolopoulou P et al (2007). Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 56 : 3977 3988.
50. Mariette X (1999). Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 33 : 93 99.
51. Mariette X, Roux S, Zhang J et al (2003). The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 : 168 171.
52. Matsumura R, Umemiya K, Kagami M et al (2002). Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome. Clin Exp Rheumatol 20 : 791 798.
53. McArthur C, Wang Y, Veno P, Zhang J, Fiorella R (2002). Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly(ADP-ribose) polymerase and alpha-fodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha. Arch Oral Biol 47 : 443 448.
54. Moutsopoulos NM, Katsifis GE, Angelov N et al (2008). Lack of efficacy of etanercept in Sjogren's syndrome correlates with failed suppression of TNF-alpha and systemic immune activation. Ann Rheum Dis 67 : 1437 1443.
55. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB (2008). Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: Findings in humans and mice. Arthritis Rheum 58 : 734 743.
56. Ogawa N, Dang H, Lazaridis K, McGuff HS, Aufdemorte TB, Talal N (1995). Analysis of transforming growth factor beta and other cytokines in autoimmune exocrinopathy (Sjogren's syndrome). J Interferon Cytokine Res 15 : 759 767.
57. Oxholm P, Daniels TE, Bendtzen K (1992). Cytokine expression in labial salivary glands from patients with primary Sjogren's syndrome. Autoimmunity 12 : 185 191.
58. Park H, Li Z, Yang XO et al (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 : 1133 1141.
59. Pers JO, Devauchelle V, Daridon C et al (2007). BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 56 : 1464 1477. (Pubitemid 46764075)
60. Prud'homme GJ, Piccirillo CA (2000). The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 14 : 23 42.
61. Ronnblom L, Alm GV (2001). An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22 : 427 431.
62. Rousset F, Garcia E, Defrance T et al (1992). Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89 : 1890 1893.
63. Rousset F, Peyrol S, Garcia E et al (1995). Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Int Immunol 7 : 1243 1253.
64. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S (2008). Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 181 : 2898 2906.
65. Schulze-Koops H, Kalden JR (2001). The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 15 : 677 691.
66. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB (2004). IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172 : 6476 6481.
67. Shiozawa S, Shiozawa K, Shimizu S et al (1990). Immunoreactive circulating alpha-interferon is low in Sjogren's syndrome. Br J Rheumatol 29 : 50 52.
68. Steinman L (2007). A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 : 139 145.
69. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R (2004a). Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 59 : 592 599.
70. Szodoray P, Jellestad S, Alex P et al (2004b). Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren's syndrome with a special emphasis on BAFF. J Clin Immunol 24 : 600 611.
71. Szodoray P, Alex P, Jonsson MV et al (2005). Distinct profiles of Sjogren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117 : 168 176.
72. Tak PP (2004). IFN-beta in rheumatoid arthritis. Front Biosci 9 : 3242 3247.
73. Taniguchi T, Takaoka A (2001). A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2 : 378 386.
74. Tishler M, Yaron I, Shirazi I, Yossipov Y, Yaron M (1999). Increased salivary interleukin-6 levels in patients with primary Sjogren's syndrome. Rheumatol Int 18 : 125 127.
75. Tzioufas AG, Voulgarelis M (2007). Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 21 : 989 1010.
76. Vitali C, Bombardieri S, Jonsson R et al (2002). Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 : 554 558.
77. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999). Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 42 : 1765 1772.
78. Vucicevic Boras V, Brailo V, Lukac J, Kordic D, Picek P, Blazic-Potocki Z (2006). Salivary interleukin-6 and tumor necrosis factor alpha in patients with drug-induced xerostomia. Oral Dis 12 : 509 511. (Pubitemid 44255413)
79. Wahl SM (2007). Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 19 : 55 62.
80. Wakamatsu E, Matsumoto I, Yasukochi T et al (2006). Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 54 : 3476 3484.
81. Wakamatsu E, Nakamura Y, Matsumoto I et al (2007). DNA microarray analysis of labial salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 66 : 844 845.
82. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA (2008). Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 38 : 2024 2033.
83. Willeke P, Schotte H, Schluter B et al (2003). Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 62 : 359 362.
84. Wilson NJ, Boniface K, Chan JR et al (2007). Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8 : 950 957.
85. van Woerkom JM, Kruize AA, Wenting-van Wijk MJ et al (2005). Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared with non-Sjogren's sicca syndrome. Ann Rheum Dis 64 : 1474 1479.
86. Wu AJ, Kurrasch RH, Katz J, Fox PC, Baum BJ, Atkinson JC (1994). Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of a human salivary gland cell line. J Cell Physiol 161 : 217 226.
87. Wu AJ, Chen ZJ, Baum BJ, Ambudkar IS (1996). Interferon-gamma induces persistent depletion of internal Ca2+ stores in a human salivary gland cell line. Am J Physiol 270 : C514 C521.